Research programme: SMP 500 - XOMAAlternative Names: SMP 500 research programme - XOMA
Latest Information Update: 30 Aug 2002
At a glance
- Originator XOMA
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gram-negative infections; Gram-positive infections
Most Recent Events
- 28 Jul 1999 Preclinical development for Gram-positive infections in USA (Unknown route)
- 28 Jul 1999 Preclinical development for Gram-negative infections in USA (Unknown route)
- 28 Jul 1999 New profile